Top Markets
Coin of the day
Mural Oncology plc Mural Oncology plc

Mural Oncology plc

MURA
Clasificación en acciones #27062
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Precio por acción
$2.04
Última sincronización: 2025-12-09
Capitalización bursátil
$35.38M
Cambio (1 día)
0.00%
Cambio (1 año)
-2.39%
País
IE
Comercio Mural Oncology plc (MURA)

Categoría

Ratio P/B de Mural Oncology plc (MURA)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Mural Oncology plc, el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Mural Oncology plc desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH